Tonghua Jinma: It is normal for new drugs to be temporarily paused during the evaluation process.

Tonghua Jinma stated on August 14th on the interactive platform that the company's new drug is currently in the normal review process. The occurrence of pauses and other situations during the review process is a normal part of the professional and comprehensive review process for new drugs. During this process, the company is actively communicating with the CDE and responding to relevant materials.